Compare BIRK & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIRK | RYTM |
|---|---|---|
| Founded | 1774 | 2008 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.8B |
| IPO Year | 2023 | 2017 |
| Metric | BIRK | RYTM |
|---|---|---|
| Price | $39.42 | $115.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $61.43 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.7M | 682.0K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.71 | $55.34 |
| Revenue Next Year | $14.30 | $86.06 |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.33 | $74.50 |
| 52 Week High | $53.53 | $122.20 |
| Indicator | BIRK | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 61.49 |
| Support Level | $37.57 | $98.59 |
| Resistance Level | $41.89 | $122.20 |
| Average True Range (ATR) | 1.80 | 5.42 |
| MACD | 0.12 | 0.83 |
| Stochastic Oscillator | 44.71 | 82.89 |
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.